Type 1 diabetes is diagnosed through a combination of blood sugar tests, autoantibody testing, and sometimes a measure of how much insulin your body still produces. The same blood sugar thresholds used to diagnose any diabetes apply here: a fasting blood sugar of 126 mg/dL or higher, an A1C of 6.5% or above, or a random blood sugar of 200 mg/dL or higher when symptoms are present. What makes the type 1 diagnosis distinct is confirming that the immune system is attacking the cells that produce insulin.
Blood Sugar Tests That Flag Diabetes
The first step is confirming that blood sugar levels are in the diabetic range. Three standard tests can do this. A fasting plasma glucose test requires at least eight hours without food; a result of 126 mg/dL or higher points to diabetes. An A1C test measures your average blood sugar over the past two to three months, and a result of 6.5% or above meets the diagnostic threshold. If you already have classic symptoms like extreme thirst, frequent urination, and unexplained weight loss, a single random blood sugar reading of 200 mg/dL or higher is enough.
In many cases, especially when someone shows up at an emergency room already very sick, the diagnosis is obvious from blood sugar alone combined with symptoms. But when results are borderline or the picture is unclear, doctors typically repeat the test or use a second type of test to confirm.
Why A1C Can Be Misleading in Type 1
A1C works by measuring how much sugar has attached to your red blood cells over their roughly three-month lifespan. It is not a direct reading of blood sugar, and that distinction matters. Anything that changes how long red blood cells survive in your body, such as anemia, kidney disease, liver problems, or inherited blood cell conditions, can throw off the result.
More importantly for type 1 diabetes, the disease sometimes develops so quickly that A1C hasn’t had time to climb. Studies have found that A1C at the 6.5% cutoff catches only about 30 to 40% of people with newly diagnosed diabetes. Fasting blood sugar picks up roughly 50%, while the oral glucose tolerance test detects around 90%. This is why doctors often rely on direct blood sugar measurements rather than A1C alone when type 1 is suspected, particularly in children and young adults whose disease can progress over weeks.
The Oral Glucose Tolerance Test
An oral glucose tolerance test (OGTT) is sometimes used when results from other tests are inconclusive or when doctors want to catch early blood sugar problems. You fast for at least eight hours, then drink a solution containing 75 grams of sugar. Blood samples are drawn before you drink it, then again at one hour and two hours afterward. A two-hour reading of 200 mg/dL or higher confirms diabetes, while 140 to 199 mg/dL indicates prediabetes or early glucose intolerance. The OGTT is particularly useful for identifying the subtle blood sugar abnormalities that appear in the early, presymptomatic stages of type 1.
Autoantibody Testing Confirms Type 1
The defining feature of type 1 diabetes is that the immune system destroys the insulin-producing beta cells in the pancreas. Autoantibody tests detect the specific immune proteins involved in that attack. A standard panel checks for four of them: antibodies against insulin itself, antibodies targeting an enzyme called GAD65, antibodies against a protein called IA-2, and antibodies against a zinc transporter known as ZnT8.
Testing positive for one or more of these autoantibodies, combined with high blood sugar, confirms type 1 diabetes. The more autoantibodies present, the more certain the diagnosis. People with type 2 diabetes test negative for all of them. In practice, autoantibody testing is what separates a type 1 diagnosis from type 2, especially in adults where the presentation can overlap. Not every doctor orders these tests upfront, but they become essential when someone doesn’t fit the typical type 2 profile: a lean young person, someone who doesn’t respond well to standard oral medications, or anyone whose blood sugar deteriorates quickly.
C-Peptide: Measuring Insulin Production
C-peptide is a byproduct released every time your pancreas makes insulin. Measuring it tells doctors how much insulin your body is still producing on its own. In type 1 diabetes, C-peptide levels are very low or undetectable because the beta cells have been destroyed. A fasting C-peptide level below 0.2 nmol/L strongly indicates type 1 diabetes and near-complete loss of beta cell function.
In type 2 diabetes, C-peptide levels are typically normal or even high because the pancreas is still making plenty of insulin; the problem is that the body doesn’t respond to it effectively. C-peptide testing is especially helpful when the diagnosis is uncertain, such as in older adults who might have a slower-developing autoimmune form of diabetes. It can also predict how soon someone will need insulin therapy: people with very low stimulated C-peptide levels tend to require insulin much sooner.
The Three Stages of Type 1 Diabetes
Type 1 diabetes doesn’t appear overnight. It progresses through three recognized stages, and modern screening can now detect it before symptoms ever appear.
In Stage 1, the immune attack has started but blood sugar levels are still completely normal. The only sign is the presence of two or more islet autoantibodies on a blood test. People in this stage feel fine and have no idea anything is wrong. Stage 2 looks similar, with autoantibodies still present, but blood sugar is now starting to creep up. Fasting glucose may reach 100 mg/dL or higher, or readings during a glucose tolerance test may be abnormal, even though the person still doesn’t have obvious symptoms. Stage 3 is when blood sugar climbs high enough to cause the classic symptoms: excessive thirst, frequent urination, fatigue, blurred vision, and weight loss.
Current clinical guidelines from the American Diabetes Association emphasize prompt evaluation for stage 3 disease in anyone found to have even one specific autoantibody (IA-2), and referral to a specialized center for people with multiple autoantibodies. This matters because catching the disease before stage 3 opens the door to treatments that can slow progression and, critically, helps avoid a dangerous first presentation in the emergency room.
When Diagnosis Happens in an Emergency
For many people, particularly children, the first sign of type 1 diabetes is a medical emergency called diabetic ketoacidosis, or DKA. Without enough insulin, the body starts breaking down fat for energy, producing acidic compounds called ketones that build up in the blood. DKA is diagnosed when blood sugar is above 250 mg/dL, blood pH drops below 7.3 (meaning the blood has become too acidic), and ketones are present in the blood or urine.
Someone in DKA typically arrives at the hospital with nausea, vomiting, abdominal pain, rapid breathing, and confusion. The diagnosis of diabetes is immediate and obvious from the blood work. Autoantibody and C-peptide testing may follow later to formally classify it as type 1, but treatment with insulin begins right away. Roughly a quarter to a third of children with type 1 diabetes are first diagnosed during a DKA episode, which is one reason screening programs for at-risk children are gaining momentum.
Distinguishing Type 1 From LADA
Latent autoimmune diabetes in adults, or LADA, is sometimes called “type 1.5” because it shares features of both type 1 and type 2. It typically appears after age 30, and unlike classic type 1, the destruction of beta cells happens gradually rather than rapidly. People with LADA often respond to oral diabetes medications at first, then slowly lose that response over months to years as their insulin production declines.
The diagnostic clues are the same ones used for type 1: positive autoantibodies (especially GAD65) and low or declining C-peptide levels. The key differences are timing and pace. In classic type 1, insulin is needed almost immediately at diagnosis. In LADA, people may go six months or longer before requiring insulin. C-peptide levels in LADA tend to start low-normal rather than undetectable, declining over time. If you’ve been diagnosed with type 2 diabetes but are lean, losing weight without trying, or finding that your medications are becoming less effective, LADA is worth investigating with autoantibody testing.
Genetic Testing and Family Screening
Certain gene variants in the HLA region of chromosome 6 dramatically affect type 1 diabetes risk. More than 60 genes have been linked to the disease, but two HLA types carry the strongest association. People who carry both the DR3 and DR4-DQ8 gene variants have the highest genetic risk. Having DR4-DQ8 alone raises risk roughly eightfold compared to the general population, while carrying DR3 increases it about threefold.
Genetic testing is not used to diagnose active type 1 diabetes. Its role is in screening, particularly for relatives of someone already diagnosed. A first-degree relative (parent, sibling, child) of a person with type 1 diabetes has a significantly higher risk of developing it. Genetic testing can identify which family members carry high-risk HLA types, and those individuals can then be monitored with periodic autoantibody testing. If autoantibodies appear, glucose monitoring with continuous glucose monitors or regular OGTTs can track progression through the presymptomatic stages, giving families and doctors a head start on treatment planning.